---
document_datetime: 2025-12-29 11:58:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sildenafil-actavis.html
document_name: sildenafil-actavis.html
version: success
processing_time: 0.1261343
conversion_datetime: 2025-12-30 20:26:34.874081
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sildenafil Actavis

[RSS](/en/individual-human-medicine.xml/65472)

##### Authorised

This medicine is authorised for use in the European Union

sildenafil Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Sildenafil Actavis](#more-information-on-sildenafil-actavis-982)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Sildenafil Actavis?

Sildenafil Actavis is a medicine that contains the active substance sildenafil. It is available as tablets (25, 50 and 100 mg).

Sildenafil Actavis is a 'generic medicine'. This means that Sildenafil Actavis is similar to a 'reference medicine' already authorised in the European Union (EU) called Viagra.

## What is Sildenafil Actavis used for?

Sildenafil Actavis is used to treat adult men with erectile dysfunction (sometimes called impotence), when they cannot get or keep a hard penis (erection) sufficient for satisfactory sexual activity. For Sildenafil Actavis to be effective, sexual stimulation is required.

The medicine can only be obtained with a prescription.

## How is Sildenafil Actavis used?

The recommended dose of Sildenafil Actavis is 50 mg taken as needed about one hour before sexual activity. If Sildenafil Actavis is taken with food, the onset of activity may be delayed compared with taking Sildenafil Actavis without food. The dose may be increased to a maximum of 100 mg or decreased to 25 mg depending on the effectiveness and side effects. Patients with liver problems or severe kidney problems should start treatment with the 25-mg dose. The maximum recommended dosing frequency is one tablet per day.

## How does Sildenafil Actavis work?

The active ingredient in Sildenafil Actavis, sildenafil, belongs to a group of medicines called phosphodiesterase-type-5 (PDE5) inhibitors. It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP). During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the *corpora cavernosa* ) to relax. This allows blood to flow into the *corpora* , producing the erection. By blocking the breakdown of cGMP, Sildenafil Actavis restores erectile function. Sexual stimulation is still needed to produce an erection.

## How has Sildenafil Actavis been studied?

Because Sildenafil Actavis is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Viagra. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Sildenafil Actavis?

Because Sildenafil Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Sildenafil Actavis been approved?

The CHMP concluded that, in accordance with EU requirements, Sildenafil Actavis has been shown to have comparable quality and to be bioequivalent to Viagra. Therefore, the CHMP's view was that, as for Viagra, the benefit outweighs the identified risk. The Committee recommended that Sildenafil Actavis be given marketing authorisation.

## Other information about Sildenafil Actavis

The European Commission granted a marketing authorisation valid throughout the European Union for Sildenafil Actavis on 10 December 2009.

For more information about treatment with Sildenafil Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Sildenafil Actavis : EPAR - Summary for the public

English (EN) (90.26 KB - PDF)

**First published:** 21/12/2009

**Last updated:** 11/05/2015

[View](/en/documents/overview/sildenafil-actavis-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-75)

български (BG) (142.22 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/bg/documents/overview/sildenafil-actavis-epar-summary-public_bg.pdf)

español (ES) (92.49 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/es/documents/overview/sildenafil-actavis-epar-summary-public_es.pdf)

čeština (CS) (116.17 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/cs/documents/overview/sildenafil-actavis-epar-summary-public_cs.pdf)

dansk (DA) (90.06 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/da/documents/overview/sildenafil-actavis-epar-summary-public_da.pdf)

Deutsch (DE) (91.47 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/de/documents/overview/sildenafil-actavis-epar-summary-public_de.pdf)

eesti keel (ET) (89.49 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/et/documents/overview/sildenafil-actavis-epar-summary-public_et.pdf)

ελληνικά (EL) (124.5 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/el/documents/overview/sildenafil-actavis-epar-summary-public_el.pdf)

français (FR) (91.88 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/fr/documents/overview/sildenafil-actavis-epar-summary-public_fr.pdf)

hrvatski (HR) (101.74 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/hr/documents/overview/sildenafil-actavis-epar-summary-public_hr.pdf)

italiano (IT) (89.98 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/it/documents/overview/sildenafil-actavis-epar-summary-public_it.pdf)

latviešu valoda (LV) (112.57 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/lv/documents/overview/sildenafil-actavis-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (113.39 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/lt/documents/overview/sildenafil-actavis-epar-summary-public_lt.pdf)

magyar (HU) (112.57 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/hu/documents/overview/sildenafil-actavis-epar-summary-public_hu.pdf)

Malti (MT) (116.86 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/mt/documents/overview/sildenafil-actavis-epar-summary-public_mt.pdf)

Nederlands (NL) (90.72 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/nl/documents/overview/sildenafil-actavis-epar-summary-public_nl.pdf)

polski (PL) (116.35 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/pl/documents/overview/sildenafil-actavis-epar-summary-public_pl.pdf)

português (PT) (90.71 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/pt/documents/overview/sildenafil-actavis-epar-summary-public_pt.pdf)

română (RO) (111.68 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/ro/documents/overview/sildenafil-actavis-epar-summary-public_ro.pdf)

slovenčina (SK) (114.97 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/sk/documents/overview/sildenafil-actavis-epar-summary-public_sk.pdf)

slovenščina (SL) (105.97 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/sl/documents/overview/sildenafil-actavis-epar-summary-public_sl.pdf)

Suomi (FI) (111.94 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/fi/documents/overview/sildenafil-actavis-epar-summary-public_fi.pdf)

svenska (SV) (91.1 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

11/05/2015

[View](/sv/documents/overview/sildenafil-actavis-epar-summary-public_sv.pdf)

## Product information

Sildenafil Actavis : EPAR - Product Information

English (EN) (221.67 KB - PDF)

**First published:** 07/05/2018

**Last updated:** 13/11/2023

[View](/en/documents/product-information/sildenafil-actavis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-181)

български (BG) (380.28 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/bg/documents/product-information/sildenafil-actavis-epar-product-information_bg.pdf)

español (ES) (258.93 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/es/documents/product-information/sildenafil-actavis-epar-product-information_es.pdf)

čeština (CS) (331.29 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/cs/documents/product-information/sildenafil-actavis-epar-product-information_cs.pdf)

dansk (DA) (230.95 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/da/documents/product-information/sildenafil-actavis-epar-product-information_da.pdf)

Deutsch (DE) (246.88 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/de/documents/product-information/sildenafil-actavis-epar-product-information_de.pdf)

eesti keel (ET) (250.54 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/et/documents/product-information/sildenafil-actavis-epar-product-information_et.pdf)

ελληνικά (EL) (394.58 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/el/documents/product-information/sildenafil-actavis-epar-product-information_el.pdf)

français (FR) (244.33 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/fr/documents/product-information/sildenafil-actavis-epar-product-information_fr.pdf)

hrvatski (HR) (317.43 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/hr/documents/product-information/sildenafil-actavis-epar-product-information_hr.pdf)

íslenska (IS) (248.44 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/is/documents/product-information/sildenafil-actavis-epar-product-information_is.pdf)

italiano (IT) (239.51 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/it/documents/product-information/sildenafil-actavis-epar-product-information_it.pdf)

latviešu valoda (LV) (416.7 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/lv/documents/product-information/sildenafil-actavis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (333.9 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/lt/documents/product-information/sildenafil-actavis-epar-product-information_lt.pdf)

magyar (HU) (360.87 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/hu/documents/product-information/sildenafil-actavis-epar-product-information_hu.pdf)

Malti (MT) (355.69 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/mt/documents/product-information/sildenafil-actavis-epar-product-information_mt.pdf)

Nederlands (NL) (234.89 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/nl/documents/product-information/sildenafil-actavis-epar-product-information_nl.pdf)

norsk (NO) (226.03 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/no/documents/product-information/sildenafil-actavis-epar-product-information_no.pdf)

polski (PL) (388.72 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/pl/documents/product-information/sildenafil-actavis-epar-product-information_pl.pdf)

português (PT) (239.35 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/pt/documents/product-information/sildenafil-actavis-epar-product-information_pt.pdf)

română (RO) (344.57 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/ro/documents/product-information/sildenafil-actavis-epar-product-information_ro.pdf)

slovenčina (SK) (336.95 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/sk/documents/product-information/sildenafil-actavis-epar-product-information_sk.pdf)

slovenščina (SL) (312.56 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/sl/documents/product-information/sildenafil-actavis-epar-product-information_sl.pdf)

Suomi (FI) (325.14 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/fi/documents/product-information/sildenafil-actavis-epar-product-information_fi.pdf)

svenska (SV) (233.18 KB - PDF)

**First published:**

07/05/2018

**Last updated:**

13/11/2023

[View](/sv/documents/product-information/sildenafil-actavis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0026 10/11/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sildenafil Actavis : EPAR - All Authorised presentations

English (EN) (8.74 KB - PDF)

**First published:** 21/12/2009

**Last updated:** 08/07/2016

[View](/en/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-472)

български (BG) (32.14 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/bg/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_bg.pdf)

español (ES) (11.63 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/es/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (14.47 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/cs/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (8.55 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/da/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (8.53 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/de/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (11.28 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/et/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (30.42 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/el/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_el.pdf)

français (FR) (12.14 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/fr/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (14.61 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/hr/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.61 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/is/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_is.pdf)

italiano (IT) (10.8 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/it/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (23.19 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/lv/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (24.08 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/lt/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (22.46 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/hu/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (22.46 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/mt/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (8.31 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/nl/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (9.12 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/no/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_no.pdf)

polski (PL) (14.21 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/pl/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_pl.pdf)

português (PT) (11.27 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/pt/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_pt.pdf)

română (RO) (22.21 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/ro/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (14.84 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/sk/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (11.44 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/sl/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.11 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/fi/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (8.77 KB - PDF)

**First published:**

21/12/2009

**Last updated:**

08/07/2016

[View](/sv/documents/all-authorised-presentations/sildenafil-actavis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sildenafil Actavis Active substance sildenafil International non-proprietary name (INN) or common name sildenafil Therapeutic area (MeSH) Erectile Dysfunction Anatomical therapeutic chemical (ATC) code G04BE03

### Pharmacotherapeutic group

Urologicals

### Therapeutic indication

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

In order for Sildenafil Actavis to be effective, sexual stimulation is required.

## Authorisation details

EMA product number EMEA/H/C/001090

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Actavis Group PTC ehf

Dalshraun 1

Opinion adopted 24/09/2009 Marketing authorisation issued 10/12/2009 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sildenafil Actavis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (132.64 KB - PDF)

**First published:** 13/04/2011

**Last updated:** 13/11/2023

[View](/en/documents/procedural-steps-after/sildenafil-actavis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Sildenafil Actavis : EPAR - Public assessment report

English (EN) (160.21 KB - PDF)

**First published:** 21/12/2009

**Last updated:** 21/12/2009

[View](/en/documents/assessment-report/sildenafil-actavis-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Sildenafil Actavis

Adopted

Reference Number: EMEA/CHMP/440521/2009

English (EN) (32.53 KB - PDF)

**First published:** 25/09/2009

**Last updated:** 25/09/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-sildenafil-actavis_en.pdf)

#### More information on Sildenafil Actavis

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 13/11/2023

## Share this page

[Back to top](#main-content)